Related to Ghent University to Leverage Roche´s LightCycler® 1536 Instrument for Cancer Research

• Opinion: A Stem of Hope for Cancer Treatments
  Evidence mounts in favor of therapies targeting cancer stem cells.
  
• Customized Cancer Vaccines Finally (Maybe) Arrive
  Positive late-stage trial results are reinstating the potential of a personalized approach to treatment.
  
• GEN Exclusive: 2009 Laskers Honor Advances in Stem Cell Technology and Cancer Therapy
  Work cited will revolutionize cancer therapy and impact a potential $700 million global stem cell market.
  
• 2009 in Review: Headline-Making Stories in the Biotech Industry
  Even though last year was marred by the economic crash, the life science sector showed significant progress.
  
• Cancer Cell Line Identity Crisis
  Researchers weigh in on the impact of incorrectly labeled cell lines on cancer research and drug development.
  
• Antibody-Drug Conjugates to Fight Cancer
  While mAbs have been extremely successful, these empowered antibodies are touted as the next big blockbusters.
  
• Ocrelizumab: One Size Does Not Fit All
  Risk of serious infections has hampered mAb’s development in RA and LE, but drug is still being tested in MS.
  
• Lupus Drug Development Remains Risky Business
  Research to understand underlying causes is, nonetheless, prompting some interest.
  
• Nanotechnology Enables Precise Cancer Targeting
  While first-generation nanodrugs reduced toxicity, next-gen treatments are being designed to increase efficacy.
  
• The $1,000 Genome: From Laboratory to Lifestyle
  How we resolve current issues with genetic testing will shape consumer genomics.
  
• What Comes After Dendreon’s Provenge?
  Success of prostate cancer vaccine has ushered in a wave of autologous vaccine development.
  
• Will a Nonautologous Cancer Vaccine Be the Next to Make It Through Approval?
  In the race to mimic Dendreon’s success with Provenge, off-the-shelf products make for attractive opportunities.
  
• Is Avastin Roche’s Achilles Heel?
  Label-expansion efforts have failed, and mAb stands to lose provisional approval in breast cancer.
  
• Tales from the Biotech Crypt: Sam Waksal Is Back in Business
  Former ImClone CEO has started a new firm, made three acquisitions including Three Rivers, and begun licensing.
  
• Weighing the Benefits of Rituximab Maintenance Therapy for FL
  Drug may be more cost-effective and improve PFS, but questions about overall survival remain.
  
• Antibody-Drug Conjugates Stage a Comeback
  Technology improvements yield fresh line of anticancer clinical candidates.
  
• Melanoma Cells: All Stem Cells in Disguise?
  Researchers believe that the cancer stem cell theory may not apply to all cancers.
  
• Getting Personal: Multigene Testing for Individual Cancer Evaluation
  Scientists find comfort in numbers, using molecular patterns as prognostic markers.